Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
28.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
06.05. | OnKure Therapeutics GAAP EPS of $1.19 | 1 | Seeking Alpha | ||
ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
06.05. | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
06.05. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 121 | GlobeNewswire (Europe) | -- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company's... ► Artikel lesen | |
06.05. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | Evercore ISI starts OnKure stock with Outperform rating | 2 | Investing.com | ||
18.03. | H.C. Wainwright cuts OnKure Therapeutics price target to $34 | 8 | Investing.com | ||
10.03. | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
10.03. | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
10.03. | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 234 | GlobeNewswire (Europe) | - PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024... ► Artikel lesen | |
10.03. | OnKure Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 191 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
04.10.24 | OnKure Therapeutics, Inc. Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million | 271 | GlobeNewswire (Europe) | -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On track to announce early clinical... ► Artikel lesen | |
03.10.24 | Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure | 243 | GlobeNewswire (Europe) | - Combined company to trade on Nasdaq under ticker "OKUR" - Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,665 | +0,02 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
SANOFI | 82,30 | +0,01 % | Minimale Kursveränderung bei Sanofi SA-Aktie (82,73 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Sanofi SA . Das Wertpapier notiert aktuell bei 82,73 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei dem Anteilsschein von... ► Artikel lesen | |
INNOCAN PHARMA | 0,145 | +2,11 % | Breaking News: Innocan Pharma - der Superstar auf der "PAINWEEK"? | ||
ASSEMBLY BIOSCIENCES | 14,250 | -3,06 % | Assembly Biosciences: ABI-4334 erreicht Studienziel - Gilead-Entscheidung steht bevor | Assembly Biosciences (WKN: A402CB) liefert weiter ab: Mit ABI-4334 fällt der erste wichtige Readout dieses Jahres positiv aus. Das HBV-Asset galt als das unsicherste im Portfolio. Die Aktie liebäugelt... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 22,500 | +1,81 % | XFRA ITH0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNEKTAR THERAP. NEW... ► Artikel lesen | |
JAGUAR HEALTH | 2,500 | -7,75 % | Jaguar Health, Inc.: Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset | Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"... ► Artikel lesen | |
ROYALTY PHARMA | 30,530 | -0,39 % | Revolution Medicines, Inc.: Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with ... | Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debtCompany moving forward with independent global... ► Artikel lesen | |
BRIDGEBIO PHARMA | 38,420 | +0,26 % | BridgeBio Pharma, Inc.: BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET | ||
CORBUS PHARMACEUTICALS | 6,350 | -7,97 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab | Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and... ► Artikel lesen | |
SOLIGENIX | 1,350 | -1,46 % | SOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results | PRINCETON, N.J., May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
KALA BIO | 4,074 | +3,19 % | KALA BIO, Inc.: KALA BIO Announces Chief Executive Officer Transition | ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative... ► Artikel lesen | |
NEUROGENE | 13,820 | -1,92 % | Craig-Hallum initiates Neurogene stock with buy rating on Rett therapy | ||
ACLARIS THERAPEUTICS | 1,240 | +0,45 % | Aclaris Therapeutics initiates Phase 1 trial for ATI-052 antibody | ||
ESSA PHARMA | 1,720 | -1,15 % | ESSA Pharma Inc: ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025 | Company continues to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 ... ► Artikel lesen | |
LYRA THERAPEUTICS | 9,260 | -30,79 % | Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22% |